Home > Haematology > ASH 2020 > Immune Thrombocytopenia > BTK inhibition provides clinically active and durable platelet response

BTK inhibition provides clinically active and durable platelet response

Presented By
Dr David J. Kuter, Massachusetts General Hospital & Harvard Medical School, USA
Conference
ASH 2020
Oral rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated a clinically active and durable platelet response and was well tolerated in patients with heavily pretreated immune thrombocytopenia (ITP). This was found in an open-label phase 1/2 study evaluating rilzabrutinib in adults with relapsed ITP who had at least 2 platelet counts <30 × 109/L in the 14 days prior to the first dose of rilzabrutinib [1]. BTK inhibition targets both adaptive and innate drivers of immune-mediated disease [2]. “BTK inhibition prevents antibody production in B cells, blocks phagocytosis in macrophages, and has additional effects on basophils and neutrophils,” Dr David J. Kuter (Massachusetts General Hospital & Harvard Medical School, USA) said. “There is no effect on T cells.” Rilzabrutinib is an oral, reversible, covalent inhibitor of BTK targeting underlying disease mechanisms of platelet destruction. As opposed to ibrutinib, rilza...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on